Abbisko Cayman Ltd (HKSE:02256) Share Price

Company Profile

Business description
Abbisko Cayman Ltd is an investment holding company that operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of medicines and differentiated small molecule oncology therapies. The company has pipeline of 21 program candidates, with a primary focus on oncology and pimicotinib has received approval from the China NMPA, and several other candidates are currently in clinical development stage. The company has only one business segment which is the development of medicines. Geographically, the company has it's concentration in European Union and Chinese mainland region.
Contact
Building 3, No. 898 Halei Road
Zhangjiang Hi-Tech Park, Pudong New Area
Shanghai
CHN
T: +86 2168912098
https://www.abbisko.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
276

Recommended

International expansion is a distraction from valuable local business.

Roy Van Keulen | 14 May 2026

The chipmaker’s IPO priced at $185, well above its initial range, and opened trading at an eye-popping $350.

Jacob Robbins | 14 May 2026

How the most traded shares in April stack up against our analysts views.

Tyger Fitzpatrick | 14 May 2026

Index	Last price	Change	% Change
All Ordinaries	8,870.60	46.70	-0.52%
CAC 40	7,953.99	128.28	-1.59%
DAX 40	23,974.48	481.78	-1.97%
Dow JONES (US)	50,063.46	370.26	0.75%
FTSE 100	10,180.61	192.32	-1.85%
HKSE	25,962.73	426.31	-1.62%
NASDAQ	26,635.22	232.88	0.88%
Nikkei 225	61,409.29	1,244.76	-1.99%
NZX 50 Index	12,965.01	60.06	-0.46%
S&P 500	7,501.24	0.00	0.00%
S&P/ASX 200	8,630.80	42.70	-0.49%
SSE Composite Index	4,135.39	42.53	-1.02%